Sisonke (Together): OPEN LABEL TRIAL COVID-19

NCT ID: NCT04838795

Last Updated: 2022-08-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 477102 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-17
• Study Completion Date: 2022-03-31

Brief Summary

To monitor the effectiveness of the single-dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) in South Africa

Detailed Description

Purpose To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa

Study design Open-label, single-arm phase 3B vaccine implementation study

Rationale South Africa is severely affected by the global COVID-19 epidemic, but currently no vaccine has been rolled out. The recent promising results of the 'ENSEMBLE' trial conducted by Janssen in South Africa, and the availability of a limited amount of vaccine doses, provide the rationale for a cohort study of vaccinated HCWs to inform the larger vaccine rollout.

Study participants Health Care workers age 18 and above working in the South African public and private health care sector (N=500 000) Study sites Department of Health Vaccine administration sites across South Africa supported by the Sisonke (Together) (VAC31518COV3012) trial Research Site Investigators and Study Staff

Study duration Participants will receive a single dose of vaccine at enrolment; to monitor outcomes the DATCOV surveillance system and NICD line list will be reviewed for up to 2 years post-vaccination.

A sub-cohort (approx. 850-1000 people) consisting of special sub-populations will be followed up at approx. 1, 3, 6 weeks and 6 months post vaccination. This group will also have outcomes monitored for up to a further 18 months, bringing their total follow-up duration to 2 years post-vaccination

Study products Ad26.COV2.S by Janssen administered as a single injection

Primary objectives • To assess the effectiveness of Ad26.COV2.S vaccine on severe COVID, hospitalizations and deaths in HCWs as compared with the general unvaccinated population in South Africa.

Secondary objectives • To estimate the incidence of symptomatic SARS CoV-2 infections in HCW

• To estimate vaccine uptake among HCWs in South Africa
• To monitor the genetic diversity of breakthrough SARS CoV-2 infections To monitor immunological responses (neutralising, non-neutralising antibodies and T cell responses) in HCWs with breakthrough infections
• To measure baseline SARS CoV-2 antibody testing to evaluate pre-existing immunity in up to 100 000 HCWs.
• In a subgroup of participants (approx. 850-1000 people) including representative sub-populations of interest, e.g. elderly, immune compromised:

• To compare serum neutralization and immune responses before and after vaccination at 0, 6 weeks and up to 6 months.
• To explore clotting parameters post vaccination at weeks 0, 1, 3.
• To monitor for asymptomatic infection

Exploratory objectives To set up a comprehensive safety desk and establish a link between the national pharmacovigilance system to assist with monitoring safety and any unexpected adverse effects

Conditions

SARS (Severe Acute Respiratory Syndrome)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Interventions

To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine

To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Age 18 and older
• Health care worker in the private or public service
• The President and Deputy President of South Africa* (The President and Deputy President of South Africa have been included in the protocol to address the issue of vaccine hesitancy. )
• Willingness and ability to comply vaccination plan and other study procedures.
• Capable of giving electronic or personal signed informed consent as described in Appendix 5, which includes compliance with the requirements in this protocol.

• Age 18 and older
• Health care worker in the private or public service
• Willingness and ability to comply with all scheduled visits, vaccination plan, laboratory tests, and other study procedures, with follow-up at an ENSEMBLE site.
• Capable of giving electronic or personal signed informed consent as described in Appendix 5, which includes compliance with the requirements in this protocol.

Exclusion Criteria

• Any significant acute or chronic medical condition, situation or circumstance that in the opinion of the PI/designee makes the participant unsuitable for participation in the study, or jeopardises the safety or rights of the participant
• Participant reports being pregnant at time of enrolment, planning conception within 3 months.
• Participants who report breastfeeding at the time of enrolment will be excluded.
• Current participation in any other research studies that would interfere with the objectives of this study. The determination of whether participation in another study would be exclusionary for a given participant will be made by the PI/designee.
• History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.
• Participants who have experienced major venous and arterial thrombosis occurring with thrombocytopenia following vaccination with any COVID-19 vaccine should not enrol in Sisonke.
• Participants with a history of heparin-induced thrombocytopenia.

Note:

• Vaccination within 14-90 days with other COVID19 or non-specific vaccines are not exclusionary but should be discussed with study PI or designee.

Conditions of interest:

We note that international reports of VITT have not identified a risk factor, nor does there appear to be any prothrombotic state that indicates a risk factor for this immune response.

Nevertheless, the Sisonke study will enrol participants with chronic history of severe clotting disorders only after consultation and approval of the study Protocol Safety Review Team (PSRT).

We have identified certain specific conditions of special interest such as:

• cerebral venous sinus thrombosis,
• antiphospholipid syndrome
• Individuals on therapeutic anticoagulants for current or previous arterial or venous thrombosis or embolism

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 105 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Department of Health of South Africa

UNKNOWN

Sponsor Role: collaborator

National Institute for Communicable Diseases, South Africa

OTHER

Sponsor Role: collaborator

KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP

UNKNOWN

Sponsor Role: collaborator

Fred Hutchinson Cancer Center

OTHER

Sponsor Role: collaborator

Hutchinson Center Research Institute of South Africa (HCRISA)

UNKNOWN

Sponsor Role: collaborator

Janssen Vaccines & Prevention B.V.

INDUSTRY

Sponsor Role: collaborator

Bio Analytical Research Corporation

INDUSTRY

Sponsor Role: collaborator

Dis-Chem Pharmacy

UNKNOWN

Sponsor Role: collaborator

BioVac

UNKNOWN

Sponsor Role: collaborator

Biocair

UNKNOWN

Sponsor Role: collaborator

Right to Care

OTHER

Sponsor Role: collaborator

Clinical Laboratory Services

OTHER

Sponsor Role: collaborator

Wits Health Consortium (Pty) Ltd

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Glenda E Gray, MBChB

Role: PRINCIPAL_INVESTIGATOR

Non-Executive Director

Locations

Nelson Mandela Academic Clinical Research Unit (NeMACRU)

Mthatha, Eastern Cape, South Africa

PHOENIX Pharma Pty Ltd

Port Elizabeth, Eastern Cape, South Africa

Josha Research

Bloemfontein, Free State, South Africa

CRISMO Research Centre, Dr Bhekithemba

Germiston, Gauteng, South Africa

Perinatal HIV Research Unit (PHRU), SOWETO

Johannesburg, Gauteng, South Africa

Wits RHI: Shandukani Research Centre

Johannesburg, Gauteng, South Africa

Themba Lethu HIV Research Unit (CHRU), Dr

Johannesburg, Gauteng, South Africa

Synexus SA - Stanza Clinical Research Centre

Pretoria, Gauteng, South Africa

Setshaba Research Centre,

Pretoria, Gauteng, South Africa

Synexus Watermeyer Clinical Research Centre,

Pretoria, Gauteng, South Africa

Ndlovu Research Centre

Pretoria, Gauteng, South Africa

The Aurum Institute: Tembisa Clinical Research Centre

Johannesburg, Gauteng - South, South Africa

Perinatal HIV Research Unit Kliptown

Johannesburg, Gauteng - South, South Africa

Botha's Hill Clinical Research Site

Bothas Hill, KwaZulu-Natal, South Africa

CAPRISA eThekwini Clinical Research Site, Dr

Durban, KwaZulu-Natal, South Africa

Chatsworth Clinical Research Site

Durban, KwaZulu-Natal, South Africa

CAPRISA Vulindlela Clinical Research Site, Dr

Durban, KwaZulu-Natal, South Africa

Qhakaza Mbokodo Research Clinic

Ladysmith, KwaZulu-Natal, South Africa

Tongaat Clinical Research Site, Dr

Tongaat, KwaZulu-Natal, South Africa

Mzansi Ethical Research Centre

Middleburg, Mpumalanga, South Africa

The Aurum Institute Klerksdorp Clinical Research Centre

Klerksdorp, North West, South Africa

FAMCRU (Family Clinical Research Unit),

Cape Town, Western Cape, South Africa

TASK Central

Cape Town, Western Cape, South Africa

TASK Clinical Research Centre

Cape Town, Western Cape, South Africa

Emavundleni Research Centre

Cape Town, Western Cape, South Africa

Khayelitsha CRS, Dr Amy Ward / Dr Graeme Meintjes

Cape Town, Western Cape, South Africa

Desmond Tutu Health Foundation CTU J52 Old Main Building Groote SchuurHospital

Cape Town, Western Cape, South Africa

Synexus Helderberg Clinical Research Centre, Dr Vera

Somerset West, Western Cape, South Africa

South African Vaccine Initiative (SATVI), Dr Angelique Kany Kany

Worcester, Western Cape, South Africa

Desmond Tutu Health Foundation - Masiphumelele Research Office

Cape Town, , South Africa

The Aurum Institute: Rustenburg Clinical Research Centre, Dr Lawrence

Rustenburg, , South Africa

Countries

South Africa

References

Jacobson BF, Schapkaitz E, Takalani A, Rowji PF, Louw V, Opie J, Bekker LG, Garrett N, Goga A, Reddy T, Zuma NY, Sanne I, Seocharan I, Peter J, Robinson M, Collie S, Khan A, Takuva S, Gray G. Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study). BMJ Med. 2023 Mar 23;2(1):e000302. doi: 10.1136/bmjmed-2022-000302. eCollection 2023.

Reference Type: DERIVED

PMID: 37063238 (View on PubMed)

Takuva S, Takalani A, Seocharan I, Yende-Zuma N, Reddy T, Engelbrecht I, Faesen M, Khuto K, Whyte C, Bailey V, Trivella V, Peter J, Opie J, Louw V, Rowji P, Jacobson B, Groenewald P, Dorrington RE, Laubscher R, Bradshaw D, Moultrie H, Fairall L, Sanne I, Gail-Bekker L, Gray G, Goga A, Garrett N; Sisonke study team. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. PLoS Med. 2022 Jun 21;19(6):e1004024. doi: 10.1371/journal.pmed.1004024. eCollection 2022 Jun.

Reference Type: DERIVED

PMID: 35727802 (View on PubMed)

Bekker LG, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, Kassanjee R, Collie S, Sanne I, Boulle A, Seocharan I, Engelbrecht I, Davies MA, Champion J, Chen T, Bennett S, Mametja S, Semenya M, Moultrie H, de Oliveira T, Lessells RJ, Cohen C, Jassat W, Groome M, Von Gottberg A, Le Roux E, Khuto K, Barouch D, Mahomed H, Wolmarans M, Rousseau P, Bradshaw D, Mulder M, Opie J, Louw V, Jacobson B, Rowji P, Peter JG, Takalani A, Odhiambo J, Mayat F, Takuva S, Corey L, Gray GE; Sisonke Protocol Team; Sisonke Study Team. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022 Mar 19;399(10330):1141-1153. doi: 10.1016/S0140-6736(22)00007-1.

Reference Type: DERIVED

PMID: 35305740 (View on PubMed)

Other Identifiers

Sisonke (Together): OPEN LABEL

Identifier Type: -

Identifier Source: org_study_id